The study hypothesis is that NT1 patients with dysbiosis in their intestinal microbiota also present a bacterial translocation with an intestinal origin, leading to a systemic inflammatory syndrome favoring an autoimmune damage destroying hypocretin neurons in the hypothalamus. The study authors suspect that microbial elements (DNA) involved in the autoimmune process could be detected in the CSF. This bacterial translocation could vary over time depending on: i) the progression of the disease and its management; ii) changing dysbiosis and: iii) the increase in intestinal permeability and inflammation. conditions: Narcolepsy Type 1 conditions: Bacterial Translocation studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 120 type: ESTIMATED name: Blood sample name: Stool sample name: CSF sample measure: Plasma bacterial translocation profiles between groups measure: Plasma bacterial translocation profiles in NT1 patients measure: Taxonomic characteristics of DNA in the CSF of NT1 patients according to narcolepsy severity measure: Taxonomic characteristics of plasma bacterial DNA in patients with high bacterial translocation measure: Taxonomic characteristics of plasma bacterial DNA in patients with high bacterial translocation measure: Beta diversity of the intestinal microbiota between groups measure: Beta diversity of the intestinal microbiota in NT1 patients measure: Alpha diversity of the intestinal microbiota between groups measure: Alpha diversity of the intestinal microbiota in NT1 patients measure: Composition of the intestinal microbiota between groups measure: Composition of the intestinal microbiota between groups measure: Plasma Intestinal Fatty Acid Binding Protein (i-FABP) profile between groups measure: Plasma Intestinal Fatty Acid Binding Protein (i-FABP) profile in NT1 patients measure: Plasma LPS-binding Protein (LBP) profile between groups measure: Plasma LPS-binding Protein (LBP) profile in NT1 patients measure: Plasma Soluble CD14 profile between groups measure: Plasma Soluble CD14 profile in NT1 patients measure: Age of onset of symptoms in NT1 patients measure: Duration of disease progression in NT1 patients measure: Severity of sleep-related symptoms in NT1 patients measure: Severity of narcolepsy symptoms in NT1 patients measure: Description of comorbidities in NT1 patients measure: Sleep onset latency in NT1 patients measure: Number of rapid eye movement sleep episodes in NT1 patients measure: Orexin levels in CSF in NT1 patients sex: ALL minimumAge: 10 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Nîmes University Hospital city: Nîmes state: Gard zip: 30029 country: France name: Anissa MEGZARI role: CONTACT phone: +33 4 66 68 42 36 email: drc@chu-nimes.fr name: Catherine DUNYACH-REMY role: PRINCIPAL_INVESTIGATOR name: Jean-Philippe LAVIGNE role: SUB_INVESTIGATOR name: Béatrix ABRIL role: SUB_INVESTIGATOR lat: 43.83333 lon: 4.35 facility: Centre Hospitalier Universitaire de Montpellier city: Montpellier country: France name: Yves DAUVILLIERS role: CONTACT email: y-dauvilliers@chu-montpellier.fr name: Yves DAUVILLIERS role: PRINCIPAL_INVESTIGATOR name: Lucie BARATEAU role: SUB_INVESTIGATOR lat: 43.61092 lon: 3.87723 hasResults: False